T1912

Paclitaxel

from Taxus yannanensis, powder

• Wzór empiryczny (zapis Hilla): C₄₇H₅₁NO₁₄
• Numer CAS: 33069-62-4
• Masa cząsteczkowa: 853.91
• Beilstein: 1420457
• Numer MDL: MFCD00869953
• Kod UNSPSC: 12161501
• Identyfikator substancji w PubChem: 24899998
• NACRES: NA.77

Właściwości

• pochodzenie biologiczne: Taxus yannanensis
• Poziom jakości: 200
• Postać: powder
• kolor: white
• mp: 213 °C (dec.) (lit.)
• rozpuszczalność: DMSO: 50 mg/mL (can be stored frozen for several months); acetonitrile: soluble; ethanol: soluble; methanol: soluble (undergoes transesterification)
• spektrum działania antybiotyku: neoplastics
• Tryb działania: DNA synthesis | interferes
• inicjator: Bristol-Myers Squibb
• temp. przechowywania: 2-8°C
• ciąg SMILES: [H][C@@]12C[C@H](O)[C@@]3(C)C(=O)[C@H](OC(C)=O)C4=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c5ccccc5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c6ccccc6)c7ccccc7
• InChI: 1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
• Klucz InChI: RCINICONZNJXQF-MZXODVADSA-N
• informacje o genach: human ... BCL2(596) , TUBA1A(7846) , TUBA1B(10376) , TUBA1C(84790) , TUBA3C(7278) , TUBA3E(112714) , TUBA4A(7277) , TUBB(203068) , TUBB1(81027) , TUBB2A(7280) , TUBB2B(347733) , TUBB3(10381) , TUBB4A(10382) , TUBB4B(10383) , TUBB6(84617) , TUBB8(347688)

Opis

Opis ogólny

Chemical structure: taxoide

Zastosowanie

Paclitaxel has been used to study PREP2-tubulin interactions using coimmunoprecipitation assays on NIH3T3 cell extracts. This drug has also been used to stabilize tubulin obtained from pig brain.

Działania biochem./fizjol.

Paclitaxel is a potent anti-neoplastic and anti-mitotic taxane drug, which binds to the N-terminus of β-tubulin and and stabilizes microtubules arresting the cell cycle at the G2/M phase. The microtubule damage induces apoptosis through a JNK-dependent pathway followed by a JNK-independent pathway, perhaps related to the activation of protein kinase A (PKA) or of Raf-1 kinase, resulting in phosphorylation of Bcl-2. A major metabolite via CYP2CB is 6α-hydroxypaclitaxel (6α-OHP).

Cechy i korzyści

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Przestroga

Paclitaxel undergoes transesterification in methanol and hydrolyzes in aqueous solutions.

Uwaga dotycząca przygotowania

Paclitaxel is soluble in DMSO at 50 mg/ml and can be stored frozen for several months. It is also soluble in methanol (undergoes transesterification), acetonitrile and ethanol. Paclitaxel is rapidly destroyed in weakly alkaline, methanolic solutions and in strongly acidic methanolic solutions (1:1 of methanol:concentrated HCl). It is also soluble in a mixture of 50% Cremophor EL and 50% anhydrous ethanol.

This page may contain text that has been machine translated.

Informacja o środkach bezpieczeństwa

• Piktogramy: GHS08
• Hasło ostrzegawcze: Danger
• Zwroty wskazujące rodzaj zagrożenia: H341,H360FD,H372
• Zwroty wskazujące środki ostrożności: P202 - P260 - P264 - P280 - P308 + P313 - P405
• Klasyfikacja zagrożeń: Muta. 2 - Repr. 1B - STOT RE 1
• Organy docelowe: Central nervous system,Bone marrow,Cardio-vascular system
• Kod klasy składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• Klasa zagrożenia wodnego (WGK): WGK 3
• Temperatura zapłonu (°F): Not applicable
• Temperatura zapłonu (°C): Not applicable
• Środki ochrony indywidualnej: Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges